As per DelveInsight, the Duchenne Muscular Dystrophy Market is expected to achieve more than 8,000 million in revenue in the 7 Major Market (i.e. the United States, Germany, France, Italy, Spain, UK, and Japan) by the year 2030, owing to the launch of recent exon-skipping therapies along with expected approvals of the emerging therapies. The side effect associated with Steroids with the current standard of care is one of the significant problems faced by DMD patients. To provide an effective therapeutic solution, some of the leading companies at the global level are diligently involved in the development of new therapies.
Currently, Sarepta Therapeutics is leading the Duchenne Muscular Dystrophy Therapeutics Market with a strong, extensive pipeline and three approved products. Another key player, PTC Therapeutics, has two approved products. To further strengthen the therapeutics pipeline, some of the prominent companies such as Daiichi Sankyo, Pfizer, Solid Biosciences, Reveragen Biopharma, Santhera Pharmaceuticals, Italfarmaco, Taiho Pharmaceutical, FibroGen, Antisense Therapeutics, Capricor Therapeutics, and several others are investigating their drug candidates to improve the treatment outlook. Along with the emerging therapies, some of the factors such as the increase in research and development, awareness, and newborn screening are further expected to boost the diagnosis and treatment for the affected patient pool.
Read more: Duchenne Muscular Dystrophy Therapeutic Trials